Bank of America Securities Maintains Buy on Sanofi (SNY)

Sanofi (NASDAQ:SNY) is one of the Ridiculously Cheap Stocks to Buy According to Analysts. On September 22, Bank of America Securities analyst Sachin Jain maintained a Buy rating on Sanofi (NASDAQ:SNY) with a price target of €115.

Jain highlighted the company’s pipeline as one of the key reasons behind the positive rating. He noted that Sanofi (NASDAQ:SNY)’s Brivisimab trial data looks strong, especially in the high efficacy segment. In addition, trials in Crohn’s disease and ulcerative colitis show the drug’s broad potential.\

Similarly, Amlitelimab has received positive feedback from key opinion leaders, and the data came in better than expected. Jain believes that the convenience it provides, along with its long-lasting effects, could lead to commercial success. Lastly, Tolebrutinib is also seen as promising in the secondary progressive multiple sclerosis market, as the market is large and analysts expect strong sales.

Sanofi (NASDAQ:SNY) is a France-based healthcare company that develops, manufactures, and markets therapeutic solutions.

While we acknowledge the potential of SNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.